- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Patent holdings for IPC class A61K 31/517
Total number of patents in this class: 6563
10-year publication summary
|
342
|
333
|
354
|
388
|
407
|
468
|
411
|
537
|
472
|
9
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Genentech, Inc. | 4011 |
101 |
| Boehringer Ingelheim International GmbH | 4596 |
87 |
| Novartis AG | 10511 |
78 |
| The Regents of the University of California | 20315 |
75 |
| Bristol-myers Squibb Company | 4793 |
57 |
| F. Hoffmann-La Roche AG | 7895 |
52 |
| AstraZeneca AB | 2834 |
52 |
| Array BioPharma Inc. | 473 |
50 |
| Dana-Farber Cancer Institute, Inc. | 2621 |
47 |
| Gilead Sciences, Inc. | 2112 |
47 |
| Merck Patent GmbH | 5735 |
46 |
| Amgen Inc. | 4278 |
45 |
| Celgene Corporation | 1397 |
43 |
| Sunshine Lake Pharma Co., Ltd. | 608 |
42 |
| Merck Sharp & Dohme LLC | 3737 |
40 |
| Astellas Pharma Inc. | 1048 |
39 |
| Board of Regents, The University of Texas System | 5959 |
38 |
| Kadmon Corporation, LLC | 98 |
37 |
| Resverlogix Corp. | 54 |
36 |
| Hoffmann-La Roche Inc. | 3559 |
34 |
| Other owners | 5517 |